TP53 defects frequently arise in CLL relapse after chemoimmunotherapy despite being undetectable at the time of diagnosis [8, 9] and are strongly associated with chemotherapy resistance [10, 11]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.